24.32 USD
▲+0.25+1.04%
盘后 29.27 0.00%
2026-09-15
市值
$3.14B
市盈率
—
EPS
-3.86
股息率
—
52 周区间
11.30 – 31.74
成交量
1.93M
Beta
0.81
目标价
38.75
52W 低 11.3052W 高 31.74
价格走势
公司简介
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2α inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in...